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Cause of variable therapeutic efficiency of anglotensin converting
enzyme inhibitor on glomerular lesions. We tested the effect of anglo-
tensin I converting enzyme inhibitor (ACEI) on established glomerular
sclerosis. Starting eight weeks after subtotal nephrectomy (sNPX), rats
were given enalapril for four weeks in a dose of 50 (Group II, N = 5) or
200 mg/liter drinking water (Group III, N = 5). A third group of sNPX
rats not given ACEI served as control (Group I, N = 10). Glomerular
sclerosis index (SI, 0 to 4 scale) was assessed three-dimensionally on
serial thin sections for individual glomeruli at biopsy (Bx, 8 weeks), and
divided into four different ranks of severity and compared to autopsy
(Ax, 12 weeks). In Group I control rats, 48% of the glomeruli at Bx had
SI between 0 and I (rank I, average: 0.49 0.06), 36% between I and
2 (rank 2, average: 1.53 0.06), 9% between 2 and 3 (rank 3, average:
2.45 0.12) and 7% between 3 and 4 (rank 4, average: 3.54 0.10).
Glomeruli of the same rats at Ax were ranked according to severity of
sclerosis, and then divided into percentile groups, corresponding to the
percent of distribution at Bx. The 48% least sclerotic glomeruli at Ax
had average SI of 0.69 0.08, the next 36% 2.58 0.11, and next 9%
3.97 0.02 and the most sclerotic 7% 4.00 0.00. Thus, sclerosis
advanced during the last four weeks after biopsy in all glomeruli, with
more accelerated progression occurring toward later stages of sclerosis.
The Bx and Ax specimens of Group II rats were analyzed in an identical
fashion, showing virtually no appreciable increase in SI from Bx to Ax
in glomeruli with SI < 2.0 at Bx. In contrast, SI increased in the most
sclerotic glomeruli as much as that found in Group I control rats. SI at
the whole kidney level, assessed on a single thin section, in Group I
increased from Bx to Ax, on average by 176 58% (P < 0.005). SI also
increased in Group II, but to a significantly lesser degree, on average by
49 17%. More remarkably, whole kidney SI decreased markedly and
significantly in two Group III rats by 57 to 71% (on average 12 24%
reduction for all). From 8 to 12 weeks both systemic and glomerular
pressures were normalized (— 112 mm Hg and —52 mm Hg, respec-
tively) in Group It and Group 1!!, contrasting the typically elevated
values in Group I (-- 180 mm Hg and -'-63 mm Hg). These results
indicate that ACE! exerts variable effect on established glomerular
sclerosis even within the same kidney. Thus, whereas ACEI has little or
no effect on glomeruli with advanced sclerosis, it effectively preserves
the structure of glomeruli with early or no sclerotic lesions. Moreover,
ACE! in dosages in excess of required antihypertensive dose imparts
additional benefit to glomerular structure, having a potential to reverse
early glomerular lesions.
Once clinical signs of progressive deterioration of renal
function have commenced, even vigorous attempts to control
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the primary disease regularly fail to forestall progression to
end-stage kidney [1]. For this reason, a recent focus of inves-
tigation has been the search for an effective measure for
amelioration of this progression in high-risk patients. In addi-
tion to dietary protein intake restriction [2], antihypertensive
medication (particularly angiotensin I converting enzyme inhib-
itor [ACEI]) is attractive in view of its remarkable effectiveness
in attenuating the progressive deterioration of glomerular archi-
tecture which has been repeatedly demonstrated in animal
studies [3, 4].
In contrast to ACEI's dramatic effect in animals, results of
recent studies with ACE! in human chronic renal disease have
been unrevealing [5, 61. A potential reason for the difference in
responsiveness to ACE! between humans and animals is,
obviously, species specificity. However, another plausible ex-
planation may lie in the difference in the chronicity of the
disease between humans and rats at the onset of ACE! admin-
istration. That is, whereas therapeutic intervention is consid-
ered in humans only when patients are brought to medical
attention due to signs of renal failure, experimental therapeutic
measures including ACE! have been used routinely from the
onset of disease in animals when nephrons are intact function-
ally and structurally. Given the notion recently derived from
animal studies that the effectiveness of ACE! in protecting the
glomerular structure from progressive deterioration correlates
poorly with ACEI's antihypertensive effect [4, 7], it is also
conceivable that the dosages of ACE! which have been chosen
on the basis of its antihypertensive effects in human versus
animal studies may not be equivalent, when their effectiveness
in protecting glomerular structure is concerned. The present
series of studies was conducted to search for the answers to
these questions.
Methods
General
Experiments were performed in adult male Munich-Wistar
rats weighing 200 to 240 grams. All rats underwent subtotal
nephrectomy, that is, right nephrectomy and ligation of two or
three main branches of the left renal artery by silk ligature to
leave approximately 1/6 to 1/8 total kidney tissue mass. The
animals were allowed free access to regular rat chow and tap
water before and after subtotal nephrectomy. Systolic arterial
pressure (AP) and BUN were measured periodically, the former
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Group I (No ACEI) 4
Group II (Low ACEI) 4
Group Ill (Nigh ACEI) 4
I I
8 weeks 12 weeks Fig. 1. Schematic presentation of the experimental
Renal protocols for Group I (No ACE!), Group II (Low
autopsy ACE!) and Group III (High ACE!) studies.
by the tail cuff method [8]. During the procedures of subtotal
nephrectomy, kidney biopsy or micropuncture measurements
detailed below, animals were anesthetized with sodium pento-
barbital (Nembutal, Abbott Laboratories, North Chicago, Illi-
nois, USA; 25 to 30 mg/kg body weight, i.p.). All surgical
procedures were carried out through abdominal incision in a
sterile fashion. At the completion of study, kidneys were
harvested under pentobarbital anesthesia.
Experimental groups
Group I: Animals not treated with ACEI, N = 10. Eight weeks
after subtotal nephrectomy, animals underwent left kidney
remnant biopsy using the method described by Adler et al [9].
Briefly, a small portion of the upper pole of the kidney was
surgically removed, and bleeding from the biopsy wound con-
trolled with application of gelfoam. The renal tissue thus
obtained was processed for histological examination as de-
scribed below. Of the animals thus prepared, those which were
found to have similar whole kidney sclerosis index (specified
below) on biopsy specimens were paired, and one rat from each
pair assigned to Group I and its partner to Group II (Fig. I).
Group I and Group II were therefore assured to have compa-
rable degree of glomerular sclerosis before they were placed on
group-specific experimental protocols. Animals which did not
have appropriate partners were excluded from further study.
Following biopsy, Group I animals were returned to animal
cages after recovery from anesthesia, and observed without
ACE! administration until the completion of study. Mean
glomerular capillary hydraulic pressure (P0) was measured at
10 weeks after subtotal nephrectomy in accord with the proce-
dures described below, and animals were sacrificed for mor-
phologic studies at 12 weeks after subtotal nephrectomy.
Group II: Animals treated with "low dose" ACE!, N = 5.
Group II animals were prepared in a fashion identical to that of
Group I except that, within two days of renal biopsy, animals
were given enalapril (enalapril maleate, Merck Sharp & Dohme
Research Laboratories, Rahway, New Jersey, USA) in a dose
of 50 mg/liter drinking water for four weeks.'
Group II!: Animals treated with "high dose" ACE!, N = 5.
Group III animals underwent subtotal nephrectomy, and renal
biopsy at eight weeks in an identical manner as Group I and H.
Following biopsy, animals with whole kidney sclerosis index
not comparable to that of Group I and II were excluded from
By measuring daily water intake using metabolic cage, average
intake of enalapril in Group II (low dose ACEL) was calculated to be 12
mg/kg/day (average of 5 rats), and that in Group LII (high dose AC El)
was 48 mg/kg/day (N = 5).
the study. These rats were then treated with enalapril in a dose
of 200 mg/liter drinking water for four weeks, starting within
two days of renal biopsy.' GCwas measured at 10 weeks; rats
were sacrificed for morphologic studies at 12 weeks after the
subtotal nephrectomy.
Micropuncture measurement of P
was measured at 10 weeks after subtotal nephrectomy
under anesthesia with a continuous recording, servo-nulling
pressure system (model 4A, Instrumentation for Physiology and
Medicine, San Diego, California, USA). In animals anesthe-
tized with pentobarbital, a micropipette with outer tip diameter
of —2 pm and containing 2.0 MNaCl was advanced directly into
Bowman's space and the glomerular capillary network. If a
steady pressure tracing was not obtained on the first or second
attempt, the glomerulus was discarded from the study. Hydrau-
lic output from the servo-null system was coupled electronically
to a channel of a direct-writing recorder (Recorder 2400S,
Gould Inc., Cleveland, Ohio, USA) by means of a pressure
transducer. All the micropuncture measurements were made on
rats in a hydropenic condition [10].
Histological study
Light microscopic studies were performed on the biopsy and
autopsy specimens obtained from the same animal. Tissue was
immersion fixed in 10% neutral buffered formalin for a minimum
of four hours, routinely processed and embedded in paraffin.
Periodic acid-Schiff stained sections (3 sm thickness) of biopsy
and autopsy specimens were examined. In Group I and II
studies serial sections were made for the three-dimensional
analysis on whole glomerular corpuscles specified below.
Glomerular sclerosis. A semiquantitative score (sclerosis
index) was used to evaluate the degree of glomerular sclerosis
using the method of Raij, Azar and Keane [11]. Sclerosis was
defined as collapse and/or obliteration of the glomerular capil-
lary tuft accompanied by hyalin material, increase of mesangial
matrix and/or adhesions of the tuft to Bowman's capsule. On
serially sectioned specimens, a minimum of ten sections dis-
playing even distribution throughout each glomerulus was ex-
amined and severity of sclerosis was graded from 0 to 4+ for
each section. Thus, a I + lesion represented involvement of up
to 25% of glomerulus, while 4+ represented sclerosis of 75 to
100% of glomerulus. A single score was then obtained for each
glomerulus by averaging the scores from these multiple sec-
tions. Using this method the degree of glomerular sclerosis was
determined in greater than 13 glomeruli randomly chosen from
surface through the deep cortex in each remnant kidney of
Group I and II rats. A whole kidney sclerosis index was also
o week
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Table 1. Systolic arterial pressure (AP) and glomerular capillary
pressure (P6) at 10 weeks after sNPX in Groups I, II and III
Group
AP PGC
mm Hg
I.NoACEI 173± 7 63±3
II. Low ACEI 116 3 51 2
III. High ACEI 112 4 53
Values are given as mean I SE.
a P< 0.05 Low and High ACEI treated rats vs. No ACEI treated rats
obtained in all groups from biopsy and autopsy remnant kidney
specimens by averaging the scores for all glomeruli present on
a single thin section. In biopsy specimens with less than 40
glomeruli on a single thin section, two sections greater than 100
apart (average glomerular diameter) were analyzed. A mini-
mum of 46 glomeruli were analyzed in autopsied kidneys
(average 73 glomeruli) and greater than 50 glomeruli (average 71
glomeruli) were assessed in biopsy specimens. Change in whole
kidney SI was calculated as a percent change from biopsy SI to
autopsy SI for each rat, and these individual values were then
averaged for group means.
Glomerular size. Planar area of glomeruli was determined on
each serial section subjected to the above sclerosis index
scoring, using a computerized planimeter (Micro-plan H, Don-
santo Corp., Natick, Massachusetts, USA). The maximum
planar area (PAmax) was determined on serial sections for each
glomerulus to represent the corpuscular size of the specific
glomerulus. Change in PAmax was calculated as a percent
change from biopsy SI to autopsy SI for each rat, and these
individual values were then averaged for group means.
Analytic
BUN was measured using a BUN analyzer (BUN Analyzer
II, Beckman Instruments, Inc., Fullerton, California, USA).
Plasma sodium and potassium levels were measured by flame
photometry.
Statistical analysis
Results are expressed as mean 1 SEM. Comparisons be-
tween two groups were made using the unpaired or paired t-test
as appropriate. Sclerosis index was compared by the Mann-
Whitney U non-parametric test. Data from multiple groups
were compared using one-way ANOVA followed by multiple
comparisons by the Bonferroni method [12]. The results were
deemed statistically significant when the P value was <0.05.
Results
Systemic and glomerular pressures and serum electrolytes
Measurements made at 10 weeks revealed that both systolic
arterial and glomerular capillary hydraulic pressure were ele-
vated in Group I subtotally nephrectomized (sNPX) rats not
given ACEI, averaging 173 7 and 63 3 mm Hg, respec-
tively. In contrast, Group II and III animals given low dose
ACEI and high dose ACEI, respectively, had similarly low
levels of AP (116 3 and 112 4mm Hg, respectively) and P0
(51 2 and 53 1 mm Fig, respectively; Table 1). These values
are well within the ranges typically found in normal Munich-
Wistar rats. Thus, although the onset of administration of ACEI
Table 2. Plasma electrolytes at 12 weeks after sNPX
Group
Plasma Na Plasma K
,nEqlliter
I. No ACEI 147.4 5.3 5.3 0.8
II. Low ACE! 148.5 5.3 4.8 0.3
III. High ACEI 146.2 5.2 5.1 0.2
Values are given as mean I SE.
Fig. 2. Alterations in BUN between 8 weeks and 12 weeks after
subtotal nephrectomy. Each open column represents the mean value
measured at 8 weeks and stippled columns represent the mean value
measured at 12 weeks after subtotal nephrectomy. The vertical bars
represent one SE.
had been delayed until glomerular lesions and high systemic and
glomerular pressures were established (that is, 8 weeks post-
nephrectomy), the low dose ACEI (50 mglliter drinking water)
was sufficient to decrease both AP and GC to levels compara-
ble to those of normal animals. Moreover, the high dose ACEI
did not cause hypotension at the systemic or glomerular level.
Table 2 shows plasma electrolyte values measured at 12
weeks after sNPX. Animals given low dose ACEI and high dose
ACE! had normal levels of plasma sodium (148.5 5.3 and
146.2 5.2 mEq/liter, respectively) and plasma potassium (4.8
0.3 and 5.1 0.2 mEq/liter, respectively). Thus, high dose
ACEI, as well as low dose ACEI, had no adverse effects on
these plasma electrolyte values.
Measurements of BUN made at the time of biopsy revealed
that Group I, II and III animals at eight weeks had comparable
degree of renal failure, BUN averaging 58 4, 60 4 and 61
6 mg/dl, respectively (Fig. 2). Subsequently, BUN increased
uniformly from 8 to 12 weeks in Group I non-ACEI treated rats
on average to 79 7 mg/dl (P < 0.005). In Group II and Group
III (low and high ACEI treated rats), BUN also increased over
this time period, although less markedly (from 60 4 to 68 9
mg/dl, NS, and from 61 6 to 71 5, NS, respectively).
Glomerular morphology of biopsy and autopsy specimens
Figure 3A presents the morphological data from biopsy (left)
and autopsy (right) specimens of Group I rats, not given ACE!.
Each data point represents a value obtained from an individual
glomerulus determined by serial section analysis. The morphol-
ogy of each glomerulus was analyzed in terms of the degree of
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sclerosis (Y-axis) and the glomerular size (X-axis). As shown in
the right panel, a biphasic pattern in the size of glomeruli
became apparent at autopsy 12 weeks after sNPX. Thus, for
glomeruli with early sclerosis, the degree of sclerosis has a
positive relationship with size, and for glomeruli with advanced
sclerosis, the degree of sclerosis has a negative relationship
with size.2
Figure 3A also illustrates our method of data analysis.
Glomeruli from biopsy specimens (left) were grouped into four
different ranks of severity of glomerular sclerosis; first rank
with sclerosis index 0 to 1, second 1 to 2, third 2 to 3 and most
severe rank 3 to 4. At biopsy, 48% of glomeruli were in the first
and mildest sclerosis ranking, 36% in the second, 9% the third,
7% in the last rank, that is, most severe sclerosis. All of the data
points from the autopsy specimens were then ranked from
mildest to most advanced sclerosis, and grouped into four
categories with percentiles corresponding to those of the bi-
opsy: The first rank of the autopsy glomeruli contained the 48%
of glomeruli with the mildest sclerosis, next the 36% with the
second mildest sclerosis, the third rank had 9% and the last
rank, the 7% of glomeruli with the most advanced sclerosis. The
2 Unlike our previous study [7], we did not analyze a large number of
data from single animals, but only pooled data from five different
animals, and thus did not perform statistical analysis of this relationship
on these data.
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Fig. 3.A. Alterations in sclerosis index and maximum
planar area of remnant glomeruli between 8 weeks
(biopsy) and 12 weeks (autopsy) after subtotal
nephrectomy in Group I rats, not given ACE!. Each
data point represents a value obtained from an
individual glomerulus determined by serial section
analysis. The morphology of each glomerulus was
analyzed in terms of the degree of sclerosis (Y-axis),
and the glomerular size (X-axis). The symbol "+"
represents mean values calculated for each ranked
group. B. Relationship between sclerosis index and
maximum planar area at biopsy and autopsy in rats on
no ACE! (Group I) and low ACE! (Group H). Each of
the four closed circles (no ACE!) and four open circles
(low ACE!) at the base of arrows represents mean
values for these two indices of glomeruli with sclerosis
indices between 0-1, 1-2, 2-3 or 3-4 at the time of biopsy
(8 weeks). Each of the other four closed circles (no
ACE!) and the other four open circles (low ACEI) at
the tip of arrows represents mean values at the time of
autopsy (12 weeks) for glomeruli within the same
relative, or percentage, sclerosis rank in the autopsy
specimens as in the biopsy specimens (8 weeks).
average values calculated for data falling within each rank
(indicated by the symbol "+") are shown in Figure 3A.
In Figure 3B, these average values calculated for each ranked
group are shown as closed circles for both biopsy and autopsy
specimens of Group I ACE! non-treated animals. Thus, in
glomeruli of each sclerosis rank in sNPX rats not treated with
ACE!, sclerosis progressed during the four week period, as
indicated by the four upwardly pointing solid arrows between
closed circles. Of note, in glomeruli with mildest sclerosis at
biopsy, when compared to glomeruli at three other ranks,
progression of sclerosis (indicated by upward shift) was mark-
edly and significantly less, while those with most severe scle-
rosis became completely sclerotic. We have made the same
analysis of specimens from Group!! low ACEI-treated animals,
shown as open circles in Figure 3B. Thus, the glomeruli with
the mildest sclerosis at the time of biopsy (prior to ACE!
administration) showed no increase in the degree of sclerosis
during the four-week ACE! treatment period, as indicated by
the nearly flat arrows between the open circles seen in the lower
half of the panel (P = NS for biopsy vs. autopsy sclerosis
index). In fact, sclerosis for the second mildest percentile was
slightly less at autopsy than at biopsy (P <0.02). This is in clear
contrast to the upward shift in control rats not given ACE! with
more severe sclerosis in each rank at autopsy (P < 0.05 and <
0.0001, for biopsy vs. autopsy sclerosis in sclerosis ranks I and
2, respectively). Of note, however, even in the low ACE!-
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treated rats, glomeruli with more advanced sclerosis, that is,
those which were in the third and fourth ranks at biopsy, did
show continued progression of sclerosis, as indicated by the
upward arrows (P < 0.005). In particular, in those glomeruli
with the most advanced sclerosis at biopsy, the sclerosis
advanced just as much as that seen in rats not given ACE!.
Note that this "rate of progression" is mathematically limited,
since the upper limit for the sclerosis index is 4.0. Thus, due to
this variability in the effectiveness of ACEI on the glomerular
morphology at different stages of glomerular sclerosis, glomer-
uli tended to diverge into two subpopulations during the low
dose ACEI therapy, one with very early and the other with far
advanced sclerosis. For each percentile rank at autopsy, the
distribution of lesions was shifted so that sclerosis was more
severe in control than ACE! treated rats for each subgroup
except the most severe, where lesions were equally severe in
both groups (P < 0.005, P < 0.0001 and P <0.0005 for the three
lower percentile groups for Group I control vs. Group II ACEI
autopsy sclerosis).
The dose-dependency of the effect of ACEI on the glomerular
morphology was also examined. As described earlier, the two
dosages of ACEL employed in our study exerted remarkably
similar depressor effect on both systemic and glomerular pres-
sures. In the morphologic study, whole kidney sclerosis index
was compared among the three groups of animals: Group II
treated with ACEI in a dose of 50 mg/liter, Group III with ACEI
in a dose of 200 mg/liter and Group I without ACEI treatment.
The data are presented in Figure 4 as the percentage of change
in the sclerosis index from biopsy to autopsy specimens from
each animal. Thus, as shown in the left column, although a wide
variability was seen among Group I animals not given ACE!,
the degree of sclerosis progressed in all rats during the four
weeks with an average increase in sclerosis index of 176 58%
from 8 to 12 weeks after subtotal nephrectomy (whole kidney
sclerosis index averaging 0.64 0.10 at biopsy and 1.35 0.14
at autopsy, P < 0.005). In rats given low dose ACEL (center
column), the degree of progression of sclerosis was substan-
tially attenuated with average increase in sclerosis index of 49
17% (sclerosis index averaging 0.91 0.03 and 1.29 0.13 at
biopsy and autopsy, respectively, P < 0.05). As shown on the
right, a high dose of ACE! further attenuated the progression.
Most strikingly, our blind morphological examination of biopsy
and autopsy specimens from the same animals revealed that in
two animals, the average sclerosis index of all glomeruli exam-
ined at autopsy was significantly less than at biopsy (from 0.53
0.19 to 0.23 0.05, P < 0.005; and from 0.70 0.11 to 0.20
0.04, P < 0.0005). Sclerosis decreased in a third animal also
75
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Fig. 4. Sclerosis index percent change from biopsy to aulopsy sped-
,nens in rats on no ACE! (Group I), low ACE! (Group 1!) and high ACE!
(Group I!!). Each point represents the change in sclerosis at biopsy vs.
autopsy in each animal. Mean is indicated by bar.
(by 16%), although this did not reach statistical significance.4
Note that — 100% change represents complete disappearance of
sclerotic lesion. This marked resolution of sclerosis is even
more significant when one considers the typical rapid progres-
We have performed identically designed experiments in four addi-
tional rats, Group Ill'. These rats had more severe sNPX, and therefore
were treated with even higher doses of ACEI (enalapril, 400 mg/liter,
starting at 8 weeks after sNPX). These rats, with comparable sclerosis
as in Groups I, II and Ill at biopsy at 8 weeks (N = 4, average SI at 8
weeks, 0.72 0.15) showed the same degree of variability of respon-
siveness to ACEI. Thus, while one Group III rat showed 43% less
sclerosis at autopsy than at biopsy, the three other rats showed variable
degrees of progression, with an average increase of sclerosis index of 54
41% in these four rats. These additional data further show the
variability of responsiveness to ACE! dependent on stage of injury,
length of treatment and dose of ACE!.
i'he continued, albeit less severe progression of lesions in the
remaining rats in this group illustrates the variability of responsiveness
to therapy. It is also apparent from the literature and Group 1 and H data
that the reversal of lesions, with only minor lesions at autopsy in our
high dose group, does not occur fortuitously. In this context, "rever-
sal" and "attenuation" are not qualitatively different, in our view, but
rather represent a quantitative difference in the degree of alteration of
the pathophysiologic processes leading to sclerosis. Thus, the variable
responsiveness to ACEI therapy at both the glomerular and whole
kidney level appears to depend on stage of lesions at onset of therapy.
length of observation and dose of ACE!.
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Fig. 5. Morphology of no ACE! (Group 1) versus high ACE! (Group !!!) at biopsy and autopsy. No ACEL rats (Group I) show the expected
progression of sclerosis from biopsy (A) to autopsy (B). In contrast, high ACEL rats (Group III) have open capillary loops with reversal of sclerosis
from biopsy (C) to autopsy (D).
sion of sclerosis in this rat model, as shown by the left column.
Figure 5 A and B show glomerular histology typical of non-
ACE! treated animals at biopsy (A, left) and autopsy (B, right),
illustrating the typical progression of sclerosis which occurs in
this model. In marked contrast are the kidneys of rats given
high dose ACE!, illustrated in Figure 5 C and D. Glomeruli of
autopsy specimens (Fig. SD) show open capillary lumina and
less mesangial expansion, compared to the mesangial expansion
and the many glomerular capillary tufts obliterated by sclerosis
in the biopsy specimens (Fig. SC).
Non-treated rats showed an increase in maximum glomerular
planar area, PAmax from 8 weeks (biopsy) to 12 weeks (autop-
sy), on average by 15 13%. Of note, although average PAmax
increased comparably in low-dose ACE! Group II by 10 4%,
the standard error, reflecting the size distribution, was much
less. Thus, after low-dose ACE! administration, glomeruli
tended to diverge into two subpopulations: those with early
sclerosis with hypertrophy vs. those that progressed to severe
sclerosis with a tendency to smaller size. The intermediate
population, that is, glomeruli having moderate sclerosis with
greatest hypertrophy, was decreased. Of note, high-dose ACE!
rats showed marked increase in PAmax from biopsy to autopsy,
with average percent increase of 44 12% (mean PAmax from
13.30 1.05 x iO— mm2 to 18.66 0.73).
Discussion
To accomplish our experimental goal of assessing the respon-
siveness of glomeruli at different stages of sclerosis to ACE!, it
is ideal to inspect the morphology of the same specific glomeruli
repeatedly throughout the duration of experiment. Currently
available technology, however, does not allow any meaningful
histological analysis on the same nephrons in a repetitive
manner, since microscopic examination requires isolation, fix-
ation and/or staining of tissue specimens. To accomplish our
experimental goal despite this limitation, we performed a
unique and time-consuming data analysis on the biopsy and
autopsy specimens obtained from the same animals. Ordinarily,
even with such specimens from different time points, the
marked internephron heterogeneity characteristically present in
chronic disease precludes documentation of the historical
course of morphological changes which took place in single
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nephrons between the two periods. We overcame these adverse
circumstances by setting up a few assumptions.
The first assumption was that randomly sampled nephrons
from a kidney specimen would faithfully represent the pattern
of distribution in terms of glomerular size and the degree of
sclerosis of the entire nephron population. Obviously, for the
sample glomeruli to represent the complete histological spec-
trum of the entire population, it is essential to characterize the
histology of the whole corpuscle of the sampled glomeruli. This
can only be accomplished in a three-dimensional examination,
such as the one carried out in our present study, since glomer-
ular sclerosis is highly segmental in nature and escapes accurate
assessment if only a single thin-section specimen is examined
for each glomerulus [10, 13, 141.
The second assumption dictates that, in subtotally nephrec-
tomized animals, both untreated and treated with ACE!, the
relative stages of sclerosis among nephrons do not change,
although sclerosis may progress at varying rates. Thus, while
sclerosis progresses in all glomeruli, glomeruli with relatively
more advanced sclerosis at biopsy within a given kidney
continue to have relatively more advanced sclerosis compared
to others at autopsy.
In our study, sampled glomeruli were ranked within each
biopsy and autopsy kidney specimen on the basis of their
degree of sclerosis. Under the assumptions discussed above,
the histological difference between glomeruli at a given rank in
a biopsy specimen to glomeruli at a corresponding rank in the
autopsy specimen of the same animals was then taken to
represent the changes which actually took place in all glomeruli
that belong to this same histological rank. By similarly inspect-
ing this change for each of the four ranks of glomerular
population, we learned that, in untreated animals, sclerosis
advances slowly initially and rapidly toward the end of com-
plete scarring, since the increase in the sclerosis index during
the four-week post-biopsy period was greater in glomeruli
which already had a higher sclerosis index at the time of biopsy
(Group I, Figs. 3 A and B). When the changes in the sclerosis
index from biopsy to autopsy specimens were assessed in
similar fashion for Group II low-ACEL-treated animals, we
found that virtually no progression in sclerosis was detected in
glomeruli with early sclerosis at the time of biopsy. In contrast,
the progression to complete scarring was just as rapid in
glomeruli which already had advanced sclerosis at time of
biopsy (Group I!, Fig. 3B) as in untreated rats. Overall, our
analysis revealed that, in this model, glomeruli are highly
heterogeneous not only in their histology at a given time, but
also in their responsiveness to ACE! in terms of protection from
progressive histological damage. More specifically, glomeruli
with more advanced sclerosis, which tend to rapidly advance
even further, are more resistant to the protective effect of
ACE!.
In this regard, it should be noted that for a comparable level
of uremia, glomerular lesions are much more advanced in
humans than in the widely used animal model of subtotal
nephrectomy. In human diseases there is thought to be deteri-
oration of more or less the entire glomerular population,
whereas in the subtotally nephrectomized animals, uremia is in
large part secondary to the initial surgical loss of large number
of nephrons with relatively intact remnant glomeruli.5
Moreover, in various animal studies in models of focal
segmental sclerosis (FGS) and diabetes conducted thus far,
administration of ACE! has regularly been initiated at the onset
of disease, that is, when all of the glomeruli are structurally
intact [3, 4, 7, 14, 151. Results have been far less dramatic with
delayed onset of ACE! therapy. No effect on progression of
glomeruloscierosis was seen in a model of uninephrectomy [16],
whereas in the remnant kidney model, delayed ACE! therapy
resulted in intermediate sclerosis [17]. Our present study indi-
cates that the non-sclerotic or early sclerotic glomeruli are
particularly sensitive to ACE!. In contrast, administration of
ACE! in humans is initiated at the earliest when patients are
brought to medical attention, and more frequently only after
other therapeutic measures have been exhausted. This differ-
ence in time of administration may be the basis of the over-
whelming positive results from animal studies where ACE! was
given at the onset, in contrast to the more variable effects with
the delayed therapy in human disease.
When ACE! was given in a higher dose, a greater therapeutic
effect on the glomerular structure was achieved as illustrated in
Figure 4. Of note in this regard are recent in vivo and in vitro
experiments illustrating angiotensin I!'s wide array of effects.
Angiotensin I! resulted in hypertrophy and increased matrix
production in mesangial cells without concomitant hyperplasia
[181. Given the fact that mesangial cells share many features
with vascular smooth muscle cells, the in vitro findings that
angiotensin I! causes hypertrophy of smooth muscle cells
grown in culture and also induces the smooth muscle cell c-fos
oncogene are relevant [19]. In addition, in vivo studies have
shown that ACE! treatment inhibits myointimal proliferation
after vascular injury [20]. These experimental observations
point to the notion that angiotensin !I can exert its actions on
the mesangium and smooth muscle independently of its well-
known hemodynamic effects. Thus, both low and high doses of
ACEI were equipotent in terms of control of systemic and
glomerular pressures, yet a substantially more beneficial effect
on the glomerular structure was achieved by the higher dosage.
Of even more interest, in three of our subtotally nephrecto-
mized rats treated in the same delayed manner with a high dose
of ACE! (dosage greater than that required for normalizing
blood pressure), sclerosis was reversed with less severe lesions
at autopsy than at biopsy in these same rats. Similar findings of
reversal were seen in a recent study of puromycin nephropathy,
a non-hypertensive model of FGS. ACE! ("normal" dose) or
low protein diet was started at the onset of the experiment and
rats were sacrificed at 12, 18 or 24 weeks. At 24 weeks, sclerosis
was less than at 12 weeks in rats treated with either protocol
Hyperfiltration and hypertrophy of these remnant nephrons will
over time allow greater filtration; however, these positive effects on
GFR, hence BUN, will be offset by progressive sclerosis. Furthermore,
the decreased P0 afforded by the vasodilative effect of ACEI in
Groups !! and 111 contributes to decreased filtration. Therefore, al-
though ACEI therapy in the long run is expected to be of benefit due to
the beneficial effects on structure, in the short run, its hemodynamic
effects may rather contribute to continued elevation of BUN, as seen in
our study. Individual analysis of rats showed improvement in BUN in
those rats with most improvement in structural lesions.
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[211. Taken together, it is suggested that ACE! may modulate
the dynamic balance of production and degradation of mesan-
gial matrix, and thus be potentially capable of reversing a key
component of glomeruloscierosis. Whether this reversal is
actually a return to a structure identical to the pre-disease state
remains to be determined. In this regard, the abnormally large
glomeruli observed after high ACE! treatment is suggestive of
the possibility that the glomerular capillary network may, in
fact, have been remodeled to a structure somewhat different
from its original normal form (albeit with open glomerular
capillary loops). Further detailed morphological studies are
required to investigate this possibility. In any case, the ob-
served therapeutic intervention with high dose ACE! and
reversal of glomerulosclerosis appear appealing, especially in
view of the limited side effects seen with high-dose ACE!
therapy and the potential for dramatic effects on structure. In
this regard, ACE! may have a unique advantage relative to
other antihypertensive drugs due to its inhibition of angiotensin
II action. Unlike other common antihypertensive drugs, such as
calcium channel blockers, it can be given at a dose higher than
that required for normalizing blood pressure, so that the hemo-
dynamic-independent salutary effect of ACE! can be fully
exploited without unwanted systemic or peripheral hypoten-
sion.
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